**Crinetics Pharmaceuticals, Inc. (CRNX) shares surged by 98.7% to close at $83.53 following an acquisition announcement by Vertex Pharmaceuticals, which is set to acquire Crinetics for approximately $10 billion. The deal is anticipated to finalize in the third quarter of 2026.**
**For the upcoming quarter, Crinetics is projected to report a loss of $1.23 per share, unchanged from the previous year, while revenues are expected to hit $14.84 million, representing a staggering 1340.6% increase year-over-year. The stock currently holds a Zacks Rank of #3 (Hold).**
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
